Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: Results of the DYSlipidemia International Study (DYSIS)

血脂异常 医学 内科学 血脂谱 指南 逻辑回归 胆固醇 风险因素 病理 肥胖
作者
Shui‐Ping Zhao,Yongjun Wang,Yiming Mu,Bilian Yu,Ping Ye,Xiaowei Yan,Zhanquan Li,Yidong Wei,Baishaili M. Ambegaonakr,Dayi Hu
出处
期刊:Atherosclerosis [Elsevier BV]
卷期号:235 (2): 463-469 被引量:88
标识
DOI:10.1016/j.atherosclerosis.2014.05.916
摘要

Despite clear guideline recommendations, there is a paucity of data regarding the prevalence and type of persistent lipid profile abnormalities in patients on stable lipid-lowering therapy in China.This cross-sectional trial included 25,697 patients treated with lipid-lowering agents from 122 centres between April 2012 and October 2012; all underwent clinical examination and had their latest fasting lipid profiles while on lipid-lowering therapy recorded. Logistic regression was performed to assess predictors for lipid abnormalities classified according to current Chinese guidelines.Overall, 29.1% of patients had no lipid abnormalities, and 38.5% of patients did not achieve the therapeutic goal for low-density lipoprotein cholesterol (LDL-C), either as a single lipid anomaly or associated with low high-density lipoprotein cholesterol (HDL-C), elevated triglycerides, or both. Subjects with low risk were more likely than those with very high and high risk to be at target LDL-C levels. Furthermore, 10.4% of very high-risk patients and 11.1% of high-risk patients who attained the LDL-C goal failed to attain non-HDL-C goals. Diabetes was shown to be a strong predictor of failure in attaining non-HDL-C and both goals (OR 3.03; 3.22, 95% CI 2.58-3.55; 2.73-3.79, respectively).Although great improvements have been made over the past decade, the large majority of very high-risk and high-risk patients treated with lipid-lowing agents still had one or more manifestations of dyslipidaemia. Further clinical evidence is needed to clarify whether adding other lipid-lowering agents to a statin will be associated with additional cardiovascular risk reduction.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
玉米侠完成签到,获得积分10
刚刚
猴子的应助被花样年华采纳,获得10
刚刚
852的应助被科研通管家采纳,获得10
刚刚
共享精神的应助被科研通管家采纳,获得10
刚刚
dzy发布了新的文献求助10
刚刚
ll关闭了ll的文献求助
刚刚
汉堡包的应助被科研通管家采纳,获得10
刚刚
Ava的应助被Lily采纳,获得10
1秒前
充电宝的应助被科研通管家采纳,获得10
1秒前
在水一方的应助被chen采纳,获得30
1秒前
SciGPT的应助被科研通管家采纳,获得10
1秒前
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
arniu2008的应助被科研通管家采纳,获得20
1秒前
1秒前
乐乐的应助被科研通管家采纳,获得10
1秒前
1秒前
syvshc的应助被科研通管家采纳,获得10
2秒前
2秒前
Orange的应助被科研通管家采纳,获得10
2秒前
qducly2026的应助被科研通管家采纳,获得30
2秒前
Jasper的应助被科研通管家采纳,获得10
2秒前
牧百川发布了新的文献求助10
2秒前
传奇3的应助被科研通管家采纳,获得10
2秒前
小二郎的应助被科研通管家采纳,获得10
2秒前
演员完成签到,获得积分10
2秒前
JamesPei的应助被科研通管家采纳,获得10
2秒前
天天快乐的应助被科研通管家采纳,获得10
2秒前
3秒前
syvshc的应助被科研通管家采纳,获得10
3秒前
FashionBoy的应助被科研通管家采纳,获得10
3秒前
3秒前
Akim的应助被科研通管家采纳,获得10
3秒前
bkagyin的应助被科研通管家采纳,获得10
3秒前
tuanheqi的应助被科研通管家采纳,获得100
3秒前
Akim的应助被科研通管家采纳,获得10
3秒前
Akim的应助被科研通管家采纳,获得10
4秒前
4秒前
无极微光的应助被科研通管家采纳,获得20
4秒前
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572482
关于积分的说明 21825940
捐赠科研通 7780074
什么是DOI,文献DOI怎么找? 3433945
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480166